

# Global Direct-acting Antiviral Drugs Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GBF2401C0903EN.html>

Date: April 2024

Pages: 127

Price: US\$ 2,800.00 (Single User License)

ID: GBF2401C0903EN

## Abstracts

### Report Overview

This report provides a deep insight into the global Direct-acting Antiviral Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Direct-acting Antiviral Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Direct-acting Antiviral Drugs market in any manner.

### Global Direct-acting Antiviral Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product,

sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AbbVie Inc.

GSK

Boehringer Ingelheim

Merck

Novartis

Beximco Pharmaceuticals

Roche

Bristol-Myers Squibb Company

Gilead Sciences

Janssen (Johnson & Johnson)

Vertex Pharmaceuticals

Natco Pharma

Market Segmentation (by Type)

NS3/4A Protease Inhibitors

Nucleoside and Nucleotide NS5B Polymerase Inhibitors

NS5A Inhibitors

Non-Nucleoside NS5B Polymerase Inhibitors

## Market Segmentation (by Application)

Hospitals

Clinics

Ambulatory Surgical Centers

Pharmacies

Others

## Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

## Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Direct-acting Antiviral Drugs Market

Overview of the regional outlook of the Direct-acting Antiviral Drugs Market:

#### Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

### Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

### Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Direct-acting Antiviral Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and

restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

1.1 Market Definition and Statistical Scope of Direct-acting Antiviral Drugs

1.2 Key Market Segments

1.2.1 Direct-acting Antiviral Drugs Segment by Type

1.2.2 Direct-acting Antiviral Drugs Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

### **2 DIRECT-ACTING ANTIVIRAL DRUGS MARKET OVERVIEW**

2.1 Global Market Overview

2.1.1 Global Direct-acting Antiviral Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Direct-acting Antiviral Drugs Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

### **3 DIRECT-ACTING ANTIVIRAL DRUGS MARKET COMPETITIVE LANDSCAPE**

3.1 Global Direct-acting Antiviral Drugs Sales by Manufacturers (2019-2024)

3.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Manufacturers (2019-2024)

3.3 Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Direct-acting Antiviral Drugs Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Direct-acting Antiviral Drugs Sales Sites, Area Served, Product Type

3.6 Direct-acting Antiviral Drugs Market Competitive Situation and Trends

3.6.1 Direct-acting Antiviral Drugs Market Concentration Rate

3.6.2 Global 5 and 10 Largest Direct-acting Antiviral Drugs Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 DIRECT-ACTING ANTIVIRAL DRUGS INDUSTRY CHAIN ANALYSIS**

- 4.1 Direct-acting Antiviral Drugs Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF DIRECT-ACTING ANTIVIRAL DRUGS MARKET**

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
  - 5.5.1 New Product Developments
  - 5.5.2 Mergers & Acquisitions
  - 5.5.3 Expansions
  - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

## **6 DIRECT-ACTING ANTIVIRAL DRUGS MARKET SEGMENTATION BY TYPE**

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Direct-acting Antiviral Drugs Sales Market Share by Type (2019-2024)
- 6.3 Global Direct-acting Antiviral Drugs Market Size Market Share by Type (2019-2024)
- 6.4 Global Direct-acting Antiviral Drugs Price by Type (2019-2024)

## **7 DIRECT-ACTING ANTIVIRAL DRUGS MARKET SEGMENTATION BY APPLICATION**

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Direct-acting Antiviral Drugs Market Sales by Application (2019-2024)
- 7.3 Global Direct-acting Antiviral Drugs Market Size (M USD) by Application (2019-2024)
- 7.4 Global Direct-acting Antiviral Drugs Sales Growth Rate by Application (2019-2024)

## **8 DIRECT-ACTING ANTIVIRAL DRUGS MARKET SEGMENTATION BY REGION**



- 8.1 Global Direct-acting Antiviral Drugs Sales by Region
  - 8.1.1 Global Direct-acting Antiviral Drugs Sales by Region
  - 8.1.2 Global Direct-acting Antiviral Drugs Sales Market Share by Region
- 8.2 North America
  - 8.2.1 North America Direct-acting Antiviral Drugs Sales by Country
  - 8.2.2 U.S.
  - 8.2.3 Canada
  - 8.2.4 Mexico
- 8.3 Europe
  - 8.3.1 Europe Direct-acting Antiviral Drugs Sales by Country
  - 8.3.2 Germany
  - 8.3.3 France
  - 8.3.4 U.K.
  - 8.3.5 Italy
  - 8.3.6 Russia
- 8.4 Asia Pacific
  - 8.4.1 Asia Pacific Direct-acting Antiviral Drugs Sales by Region
  - 8.4.2 China
  - 8.4.3 Japan
  - 8.4.4 South Korea
  - 8.4.5 India
  - 8.4.6 Southeast Asia
- 8.5 South America
  - 8.5.1 South America Direct-acting Antiviral Drugs Sales by Country
  - 8.5.2 Brazil
  - 8.5.3 Argentina
  - 8.5.4 Columbia
- 8.6 Middle East and Africa
  - 8.6.1 Middle East and Africa Direct-acting Antiviral Drugs Sales by Region
  - 8.6.2 Saudi Arabia
  - 8.6.3 UAE
  - 8.6.4 Egypt
  - 8.6.5 Nigeria
  - 8.6.6 South Africa

## **9 KEY COMPANIES PROFILE**

- 9.1 AbbVie Inc.
  - 9.1.1 AbbVie Inc. Direct-acting Antiviral Drugs Basic Information

- 9.1.2 AbbVie Inc. Direct-acting Antiviral Drugs Product Overview
- 9.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Product Market Performance
- 9.1.4 AbbVie Inc. Business Overview
- 9.1.5 AbbVie Inc. Direct-acting Antiviral Drugs SWOT Analysis
- 9.1.6 AbbVie Inc. Recent Developments
- 9.2 GSK
  - 9.2.1 GSK Direct-acting Antiviral Drugs Basic Information
  - 9.2.2 GSK Direct-acting Antiviral Drugs Product Overview
  - 9.2.3 GSK Direct-acting Antiviral Drugs Product Market Performance
  - 9.2.4 GSK Business Overview
  - 9.2.5 GSK Direct-acting Antiviral Drugs SWOT Analysis
  - 9.2.6 GSK Recent Developments
- 9.3 Boehringer Ingelheim
  - 9.3.1 Boehringer Ingelheim Direct-acting Antiviral Drugs Basic Information
  - 9.3.2 Boehringer Ingelheim Direct-acting Antiviral Drugs Product Overview
  - 9.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Product Market Performance
  - 9.3.4 Boehringer Ingelheim Direct-acting Antiviral Drugs SWOT Analysis
  - 9.3.5 Boehringer Ingelheim Business Overview
  - 9.3.6 Boehringer Ingelheim Recent Developments
- 9.4 Merck
  - 9.4.1 Merck Direct-acting Antiviral Drugs Basic Information
  - 9.4.2 Merck Direct-acting Antiviral Drugs Product Overview
  - 9.4.3 Merck Direct-acting Antiviral Drugs Product Market Performance
  - 9.4.4 Merck Business Overview
  - 9.4.5 Merck Recent Developments
- 9.5 Novartis
  - 9.5.1 Novartis Direct-acting Antiviral Drugs Basic Information
  - 9.5.2 Novartis Direct-acting Antiviral Drugs Product Overview
  - 9.5.3 Novartis Direct-acting Antiviral Drugs Product Market Performance
  - 9.5.4 Novartis Business Overview
  - 9.5.5 Novartis Recent Developments
- 9.6 Beximco Pharmaceuticals
  - 9.6.1 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Basic Information
  - 9.6.2 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Overview
  - 9.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Market Performance
  - 9.6.4 Beximco Pharmaceuticals Business Overview
  - 9.6.5 Beximco Pharmaceuticals Recent Developments
- 9.7 Roche

- 9.7.1 Roche Direct-acting Antiviral Drugs Basic Information
- 9.7.2 Roche Direct-acting Antiviral Drugs Product Overview
- 9.7.3 Roche Direct-acting Antiviral Drugs Product Market Performance
- 9.7.4 Roche Business Overview
- 9.7.5 Roche Recent Developments
- 9.8 Bristol-Myers Squibb Company
  - 9.8.1 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Basic Information
  - 9.8.2 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Overview
  - 9.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Market Performance
  - 9.8.4 Bristol-Myers Squibb Company Business Overview
  - 9.8.5 Bristol-Myers Squibb Company Recent Developments
- 9.9 Gilead Sciences
  - 9.9.1 Gilead Sciences Direct-acting Antiviral Drugs Basic Information
  - 9.9.2 Gilead Sciences Direct-acting Antiviral Drugs Product Overview
  - 9.9.3 Gilead Sciences Direct-acting Antiviral Drugs Product Market Performance
  - 9.9.4 Gilead Sciences Business Overview
  - 9.9.5 Gilead Sciences Recent Developments
- 9.10 Janssen (Johnson and Johnson)
  - 9.10.1 Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Basic Information
  - 9.10.2 Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Product Overview
  - 9.10.3 Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Product Market Performance
  - 9.10.4 Janssen (Johnson and Johnson) Business Overview
  - 9.10.5 Janssen (Johnson and Johnson) Recent Developments
- 9.11 Vertex Pharmaceuticals
  - 9.11.1 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Basic Information
  - 9.11.2 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Overview
  - 9.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Market Performance
  - 9.11.4 Vertex Pharmaceuticals Business Overview
  - 9.11.5 Vertex Pharmaceuticals Recent Developments
- 9.12 Natco Pharma
  - 9.12.1 Natco Pharma Direct-acting Antiviral Drugs Basic Information
  - 9.12.2 Natco Pharma Direct-acting Antiviral Drugs Product Overview
  - 9.12.3 Natco Pharma Direct-acting Antiviral Drugs Product Market Performance
  - 9.12.4 Natco Pharma Business Overview
  - 9.12.5 Natco Pharma Recent Developments

## **10 DIRECT-ACTING ANTIVIRAL DRUGS MARKET FORECAST BY REGION**

- 10.1 Global Direct-acting Antiviral Drugs Market Size Forecast
- 10.2 Global Direct-acting Antiviral Drugs Market Forecast by Region
  - 10.2.1 North America Market Size Forecast by Country
  - 10.2.2 Europe Direct-acting Antiviral Drugs Market Size Forecast by Country
  - 10.2.3 Asia Pacific Direct-acting Antiviral Drugs Market Size Forecast by Region
  - 10.2.4 South America Direct-acting Antiviral Drugs Market Size Forecast by Country
  - 10.2.5 Middle East and Africa Forecasted Consumption of Direct-acting Antiviral Drugs by Country

## **11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)**

- 11.1 Global Direct-acting Antiviral Drugs Market Forecast by Type (2025-2030)
  - 11.1.1 Global Forecasted Sales of Direct-acting Antiviral Drugs by Type (2025-2030)
  - 11.1.2 Global Direct-acting Antiviral Drugs Market Size Forecast by Type (2025-2030)
  - 11.1.3 Global Forecasted Price of Direct-acting Antiviral Drugs by Type (2025-2030)
- 11.2 Global Direct-acting Antiviral Drugs Market Forecast by Application (2025-2030)
  - 11.2.1 Global Direct-acting Antiviral Drugs Sales (K Units) Forecast by Application
  - 11.2.2 Global Direct-acting Antiviral Drugs Market Size (M USD) Forecast by Application (2025-2030)

## **12 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Direct-acting Antiviral Drugs Market Size Comparison by Region (M USD)

Table 5. Global Direct-acting Antiviral Drugs Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Direct-acting Antiviral Drugs Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Direct-acting Antiviral Drugs Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Direct-acting Antiviral Drugs Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2022)

Table 10. Global Market Direct-acting Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Direct-acting Antiviral Drugs Sales Sites and Area Served

Table 12. Manufacturers Direct-acting Antiviral Drugs Product Type

Table 13. Global Direct-acting Antiviral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Direct-acting Antiviral Drugs

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Direct-acting Antiviral Drugs Market Challenges

Table 22. Global Direct-acting Antiviral Drugs Sales by Type (K Units)

Table 23. Global Direct-acting Antiviral Drugs Market Size by Type (M USD)

Table 24. Global Direct-acting Antiviral Drugs Sales (K Units) by Type (2019-2024)

Table 25. Global Direct-acting Antiviral Drugs Sales Market Share by Type (2019-2024)

Table 26. Global Direct-acting Antiviral Drugs Market Size (M USD) by Type (2019-2024)

Table 27. Global Direct-acting Antiviral Drugs Market Size Share by Type (2019-2024)

Table 28. Global Direct-acting Antiviral Drugs Price (USD/Unit) by Type (2019-2024)

Table 29. Global Direct-acting Antiviral Drugs Sales (K Units) by Application

Table 30. Global Direct-acting Antiviral Drugs Market Size by Application

Table 31. Global Direct-acting Antiviral Drugs Sales by Application (2019-2024) & (K Units)

Table 32. Global Direct-acting Antiviral Drugs Sales Market Share by Application (2019-2024)

Table 33. Global Direct-acting Antiviral Drugs Sales by Application (2019-2024) & (M USD)

Table 34. Global Direct-acting Antiviral Drugs Market Share by Application (2019-2024)

Table 35. Global Direct-acting Antiviral Drugs Sales Growth Rate by Application (2019-2024)

Table 36. Global Direct-acting Antiviral Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Global Direct-acting Antiviral Drugs Sales Market Share by Region (2019-2024)

Table 38. North America Direct-acting Antiviral Drugs Sales by Country (2019-2024) & (K Units)

Table 39. Europe Direct-acting Antiviral Drugs Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Direct-acting Antiviral Drugs Sales by Region (2019-2024) & (K Units)

Table 41. South America Direct-acting Antiviral Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Direct-acting Antiviral Drugs Sales by Region (2019-2024) & (K Units)

Table 43. AbbVie Inc. Direct-acting Antiviral Drugs Basic Information

Table 44. AbbVie Inc. Direct-acting Antiviral Drugs Product Overview

Table 45. AbbVie Inc. Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. AbbVie Inc. Business Overview

Table 47. AbbVie Inc. Direct-acting Antiviral Drugs SWOT Analysis

Table 48. AbbVie Inc. Recent Developments

Table 49. GSK Direct-acting Antiviral Drugs Basic Information

Table 50. GSK Direct-acting Antiviral Drugs Product Overview

Table 51. GSK Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. GSK Business Overview

Table 53. GSK Direct-acting Antiviral Drugs SWOT Analysis

Table 54. GSK Recent Developments

- Table 55. Boehringer Ingelheim Direct-acting Antiviral Drugs Basic Information
- Table 56. Boehringer Ingelheim Direct-acting Antiviral Drugs Product Overview
- Table 57. Boehringer Ingelheim Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 58. Boehringer Ingelheim Direct-acting Antiviral Drugs SWOT Analysis
- Table 59. Boehringer Ingelheim Business Overview
- Table 60. Boehringer Ingelheim Recent Developments
- Table 61. Merck Direct-acting Antiviral Drugs Basic Information
- Table 62. Merck Direct-acting Antiviral Drugs Product Overview
- Table 63. Merck Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 64. Merck Business Overview
- Table 65. Merck Recent Developments
- Table 66. Novartis Direct-acting Antiviral Drugs Basic Information
- Table 67. Novartis Direct-acting Antiviral Drugs Product Overview
- Table 68. Novartis Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 69. Novartis Business Overview
- Table 70. Novartis Recent Developments
- Table 71. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Basic Information
- Table 72. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Overview
- Table 73. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 74. Beximco Pharmaceuticals Business Overview
- Table 75. Beximco Pharmaceuticals Recent Developments
- Table 76. Roche Direct-acting Antiviral Drugs Basic Information
- Table 77. Roche Direct-acting Antiviral Drugs Product Overview
- Table 78. Roche Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 79. Roche Business Overview
- Table 80. Roche Recent Developments
- Table 81. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Basic Information
- Table 82. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Overview
- Table 83. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 84. Bristol-Myers Squibb Company Business Overview
- Table 85. Bristol-Myers Squibb Company Recent Developments
- Table 86. Gilead Sciences Direct-acting Antiviral Drugs Basic Information

- Table 87. Gilead Sciences Direct-acting Antiviral Drugs Product Overview
- Table 88. Gilead Sciences Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 89. Gilead Sciences Business Overview
- Table 90. Gilead Sciences Recent Developments
- Table 91. Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Basic Information
- Table 92. Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Product Overview
- Table 93. Janssen (Johnson and Johnson) Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 94. Janssen (Johnson and Johnson) Business Overview
- Table 95. Janssen (Johnson and Johnson) Recent Developments
- Table 96. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Basic Information
- Table 97. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Overview
- Table 98. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 99. Vertex Pharmaceuticals Business Overview
- Table 100. Vertex Pharmaceuticals Recent Developments
- Table 101. Natco Pharma Direct-acting Antiviral Drugs Basic Information
- Table 102. Natco Pharma Direct-acting Antiviral Drugs Product Overview
- Table 103. Natco Pharma Direct-acting Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 104. Natco Pharma Business Overview
- Table 105. Natco Pharma Recent Developments
- Table 106. Global Direct-acting Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)
- Table 107. Global Direct-acting Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)
- Table 108. North America Direct-acting Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
- Table 109. North America Direct-acting Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 110. Europe Direct-acting Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
- Table 111. Europe Direct-acting Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
- Table 112. Asia Pacific Direct-acting Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)



Table 113. Asia Pacific Direct-acting Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)

Table 114. South America Direct-acting Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)

Table 115. South America Direct-acting Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)

Table 116. Middle East and Africa Direct-acting Antiviral Drugs Consumption Forecast by Country (2025-2030) & (Units)

Table 117. Middle East and Africa Direct-acting Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)

Table 118. Global Direct-acting Antiviral Drugs Sales Forecast by Type (2025-2030) & (K Units)

Table 119. Global Direct-acting Antiviral Drugs Market Size Forecast by Type (2025-2030) & (M USD)

Table 120. Global Direct-acting Antiviral Drugs Price Forecast by Type (2025-2030) & (USD/Unit)

Table 121. Global Direct-acting Antiviral Drugs Sales (K Units) Forecast by Application (2025-2030)

Table 122. Global Direct-acting Antiviral Drugs Market Size Forecast by Application (2025-2030) & (M USD)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Direct-acting Antiviral Drugs
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Direct-acting Antiviral Drugs Market Size (M USD), 2019-2030
- Figure 5. Global Direct-acting Antiviral Drugs Market Size (M USD) (2019-2030)
- Figure 6. Global Direct-acting Antiviral Drugs Sales (K Units) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Direct-acting Antiviral Drugs Market Size by Country (M USD)
- Figure 11. Direct-acting Antiviral Drugs Sales Share by Manufacturers in 2023
- Figure 12. Global Direct-acting Antiviral Drugs Revenue Share by Manufacturers in 2023
- Figure 13. Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Direct-acting Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Direct-acting Antiviral Drugs Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Direct-acting Antiviral Drugs Market Share by Type
- Figure 18. Sales Market Share of Direct-acting Antiviral Drugs by Type (2019-2024)
- Figure 19. Sales Market Share of Direct-acting Antiviral Drugs by Type in 2023
- Figure 20. Market Size Share of Direct-acting Antiviral Drugs by Type (2019-2024)
- Figure 21. Market Size Market Share of Direct-acting Antiviral Drugs by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Direct-acting Antiviral Drugs Market Share by Application
- Figure 24. Global Direct-acting Antiviral Drugs Sales Market Share by Application (2019-2024)
- Figure 25. Global Direct-acting Antiviral Drugs Sales Market Share by Application in 2023
- Figure 26. Global Direct-acting Antiviral Drugs Market Share by Application (2019-2024)
- Figure 27. Global Direct-acting Antiviral Drugs Market Share by Application in 2023
- Figure 28. Global Direct-acting Antiviral Drugs Sales Growth Rate by Application (2019-2024)

Figure 29. Global Direct-acting Antiviral Drugs Sales Market Share by Region (2019-2024)

Figure 30. North America Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Direct-acting Antiviral Drugs Sales Market Share by Country in 2023

Figure 32. U.S. Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Direct-acting Antiviral Drugs Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Direct-acting Antiviral Drugs Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Direct-acting Antiviral Drugs Sales Market Share by Country in 2023

Figure 37. Germany Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Direct-acting Antiviral Drugs Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Direct-acting Antiviral Drugs Sales Market Share by Region in 2023

Figure 44. China Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Direct-acting Antiviral Drugs Sales and Growth Rate (K Units)

Figure 50. South America Direct-acting Antiviral Drugs Sales Market Share by Country in 2023

Figure 51. Brazil Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Direct-acting Antiviral Drugs Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Direct-acting Antiviral Drugs Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Direct-acting Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Direct-acting Antiviral Drugs Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Direct-acting Antiviral Drugs Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Direct-acting Antiviral Drugs Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Direct-acting Antiviral Drugs Market Share Forecast by Type (2025-2030)

Figure 65. Global Direct-acting Antiviral Drugs Sales Forecast by Application (2025-2030)

Figure 66. Global Direct-acting Antiviral Drugs Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Direct-acting Antiviral Drugs Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GBF2401C0903EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBF2401C0903EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970